Niagen Bioscience (NAGE) Accumulated Expenses (2011 - 2026)

Niagen Bioscience (NAGE) has reported Accumulated Expenses for 14 consecutive years, with $7.6 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Accumulated Expenses fell 15.79% year-over-year to $7.6 million; the TTM figure through Mar 2026 stood at $7.6 million (down 15.79% YoY), while the FY2025 annual figure was $7.7 million, down 1.22% from the prior year.
• Accumulated Expenses retreated to $7.6 million in Q1 2026 per NAGE's latest filing, from $7.7 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $10.5 million in Q1 2024 and bottomed at $6.7 million in Q2 2022.
• Historically, Accumulated Expenses has averaged $8.3 million across 5 years, with a median of $8.1 million in 2022.
• Annual changes were most pronounced in 2023 — Accumulated Expenses surged 36.07% — and 2024, when it declined 17.66%.
• Niagen Bioscience's Accumulated Expenses stood at $7.3 million in 2022, then rose by 29.39% to $9.5 million in 2023, then declined by 17.66% to $7.8 million in 2024, then decreased by 1.22% to $7.7 million in 2025, then declined by 1.31% to $7.6 million in 2026.
• Business Quant data shows NAGE's Accumulated Expenses at $7.6 million in Q1 2026, $7.7 million in Q4 2025, and $8.7 million in Q3 2025.